Gemphire Therapeutics Inc. (GEMP) Forecasted to Earn FY2017 Earnings of ($3.13) Per Share

Gemphire Therapeutics Inc. (NASDAQ:GEMP) – Jefferies Group lowered their FY2017 EPS estimates for shares of Gemphire Therapeutics in a note issued to investors on Wednesday. Jefferies Group analyst M. Andrews now forecasts that the company will post earnings per share of ($3.13) for the year, down from their previous forecast of ($2.98). Jefferies Group has a “Buy” rating and a $18.00 price target on the stock. Jefferies Group also issued estimates for Gemphire Therapeutics’ Q4 2017 earnings at ($0.54) EPS, FY2018 earnings at ($1.99) EPS, FY2019 earnings at ($2.06) EPS, FY2020 earnings at ($1.54) EPS and FY2021 earnings at ($1.36) EPS.

A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $22.00 price target (up from $21.00) on shares of Gemphire Therapeutics in a report on Tuesday, November 14th. Piper Jaffray Companies reissued an “overweight” rating and issued a $22.00 price target on shares of Gemphire Therapeutics in a report on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and issued a $31.00 price target on shares of Gemphire Therapeutics in a report on Monday, October 23rd. Finally, Roth Capital assumed coverage on shares of Gemphire Therapeutics in a report on Thursday, October 19th. They issued a “buy” rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $22.17.

COPYRIGHT VIOLATION NOTICE: “Gemphire Therapeutics Inc. (GEMP) Forecasted to Earn FY2017 Earnings of ($3.13) Per Share” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://sportsperspectives.com/2017/11/19/gemphire-therapeutics-inc-gemp-forecasted-to-earn-fy2017-earnings-of-3-13-per-share.html.

Gemphire Therapeutics (GEMP) opened at $9.50 on Friday. Gemphire Therapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $21.59.

Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.14).

Large investors have recently modified their holdings of the stock. Advisory Services Network LLC purchased a new position in shares of Gemphire Therapeutics in the 2nd quarter worth about $139,000. Renaissance Technologies LLC purchased a new position in shares of Gemphire Therapeutics in the 1st quarter worth about $184,000. Vanguard Group Inc. lifted its holdings in Gemphire Therapeutics by 137.6% during the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after purchasing an additional 17,892 shares during the last quarter. GM Advisory Group Inc. purchased a new stake in Gemphire Therapeutics during the second quarter valued at about $457,000. Finally, Comerica Bank purchased a new stake in Gemphire Therapeutics during the third quarter valued at about $850,000. 32.91% of the stock is currently owned by institutional investors.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply